Hepatitis B Therapy in Pregnancy
- Natalie H. BzowejAffiliated withCalifornia Pacific Medical Center Email author
All decisions about initiating, continuing, or stopping therapy of the hepatitis B virus (HBV) during pregnancy must include an analysis of the risks and benefits for mother and fetus. The trimester of the pregnancy and the stage of the mother’s liver disease are important factors. Treatment in the third trimester may be initiated to aid in preventing perinatal transmission, which appears to be most pronounced in mothers with high viral loads. Consideration of initiating treatment in the third trimester should occur after a high viral load is documented in the latter part of the second trimester, to allow adequate time for initiation of antiviral therapy with significant viral suppression before delivery. This discussion should include the topic of breastfeeding, because it is generally not recommended while receiving antiviral therapy. Currently, lamivudine and tenofovir appear to be the therapeutic options with the most reasonable safety data in pregnancy.
KeywordsHepatitis B Pregnancy Perinatal transmission Treatment Antiviral Nucleoside Nucleotide Lamivudine Tenofovir
- Hepatitis B Therapy in Pregnancy
- Open Access
- Available under Open Access This content is freely available online to anyone, anywhere at any time.
Current Hepatitis Reports
Volume 9, Issue 4 , pp 197-204
- Cover Date
- Print ISSN
- Online ISSN
- Current Science Inc.
- Additional Links
- Hepatitis B
- Perinatal transmission
- Industry Sectors
- Author Affiliations
- 1. California Pacific Medical Center, 2340 Clay Street, Suite 312, San Francisco, CA, 94115, USA